Zawada E T, Brickman A S, Maxwell M H, Tuck M
J Clin Endocrinol Metab. 1980 May;50(5):912-5. doi: 10.1210/jcem-50-5-912.
Patients with primary hyperparathyroidism are frequently hypertensive. Studies were performed to determine whether the hypertension in this disorder could be corrected by saralasin infusion. Five patients with primary hyperparathyroidism and one patient with secondary hyperparathyroidism were salt depleted before saralasin testing by the administration of 1 mg/kg furosemide at 1700 h on the evening before testing. Blood pressure was measured every 2 min by an automatic recording device. Saralasin was given as a continuous iv infusion of 1, 3, 6, and 10 micrograms/kg . min for 30 min. Blood for measurement of PRA was drawn 4 min before, immediately before, and 4, 8, 12, 16, 22, 30, 60, and 90 min after the infusion was begun. Saralasin did not reduce blood pressure in these patients. The mean postsaralasin blood pressure (12--20 min after the start of the infusion) was 155/102 mm Hg compared to the control blood pressure of 156/101 mm Hg (blood pressure at -4 and 0 min). The inability of saralasin to effect a vasodepressor response was unexpected, since the mean PRA before saralasin infusion was elevated at 1895 ng/dl . 3 h (normal range, 409--818 ng/dl . 3 hr; 95% confidence limits). These studies suggest that the hypertension associated with hyperparathyroidism is not renin dependent.
原发性甲状旁腺功能亢进患者常伴有高血压。开展了多项研究以确定该病症中的高血压是否可通过静脉输注沙拉新得到纠正。在进行沙拉新测试前，对5例原发性甲状旁腺功能亢进患者和1例继发性甲状旁腺功能亢进患者进行了限盐处理，方法是在测试前一晚17:00给予1mg/kg速尿。通过自动记录装置每2分钟测量一次血压。以1、3、6和10微克/千克·分钟的速度持续静脉输注沙拉新30分钟。在输注开始前4分钟、即将开始前、开始后4、8、12、16、22、30、60和90分钟采集血样以测定血浆肾素活性（PRA）。沙拉新未能降低这些患者的血压。输注沙拉新后的平均血压（输注开始后12 - 20分钟）为155/102mmHg，而对照血压为156/101mmHg（-4和0分钟时的血压）。沙拉新未能产生血管减压反应出乎意料，因为输注沙拉新前的平均PRA升高至1895ng/dl·3小时（正常范围为409 - 818ng/dl·3小时；95%置信区间）。这些研究表明，与甲状旁腺功能亢进相关的高血压并非肾素依赖性。
